Corrigendum to <‘Novel therapeutic strategies for multiple myeloma’> <[Experimental Hematology 2015; 43: 732-741](S0301472X1500137X)(10.1016/j.exphem.2015.04.010);Novel therapeutic strategies for multiple myeloma

Experimental Hematology

Volumn 43, Issue 8, 2015, Pages 732-741

  Mimura, Naoya ^a   Hideshima, Teru ^b   Anderson, Kenneth C ^b  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BELINOSTAT; BORTEZOMIB; CARFILZOMIB; DACINOSTAT; DENDRITIC CELL VACCINE; DEXAMETHASONE; DNA METHYLTRANSFERASE INHIBITOR; ENZYME INHIBITOR; EPIGENETIC READER DOMAIN INHIBITOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LENALIDOMIDE; MKC 3946; PANOBINOSTAT; PBS 1086; PHOSPHODIESTERASE V INHIBITOR; PIDILIZUMAB; PLACEBO; PROTEIN IRE1; RICOLINOSTAT; ROMIDEPSIN; TANESPIMYCIN; THALIDOMIDE; TUBACIN; UBIQUITIN PROTEIN LIGASE; UNC 1999; UNCLASSIFIED DRUG; VORINOSTAT; X BOX BINDING PROTEIN 1; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DIARRHEA; DOWN REGULATION; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; EPIGENETICS; FATIGUE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; HUMANS; MULTIPLE MYELOMA; TUMOR MICROENVIRONMENT;

EID: 84939144934     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2021.08.007     Document Type: Erratum

References (154)

1. Laubach J., Richardson P., Anderson K. Multiple myeloma. Annu Rev Med 2011, 62:249-264.
2. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
3. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
4. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P.G., Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012, 9:135-143.
5. Ocio E.M., Richardson P.G., Rajkumar S.V., et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014, 28:525-542.
6. Leleu X., Karlin L., Macro M., et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood 2015, 125:1411-1417.
7. Schroder M., Kaufman R.J. The mammalian unfolded protein response. Annu Rev Biochem 2005, 74:739-789.
8. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
9. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008, 7:1013-1030.
10. Todd D.J., Lee A.H., Glimcher L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008, 8:663-674.
11. Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001, 107:881-891.
12. Lee A.H., Iwakoshi N.N., Glimcher L.H. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol 2003, 23:7448-7459.
13. Harding H.P., Zhang Y., Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999, 397:271-274.
14. Yoshida H., Okada T., Haze K., et al. ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. Mol Cell Biol 2000, 20:6755-6767.
15. McCullough K.D., Martindale J.L., Klotz L.O., Aw T.Y., Holbrook N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001, 21:1249-1259.
16. Tabas I., Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 2011, 13:184-190.
17. Aronson L.I., Davies F.E. DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 2012, 97:1119-1130.
18. Vincenz L., Jager R., O'Dwyer M., Samali A. Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma. Mol Cancer Ther 2013, 12:831-843.
19. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
20. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
21. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
22. Hideshima T., Anderson K.C. Biologic impact of proteasome inhibition in multiple myeloma cells-from the aspects of preclinical studies. Semin Hematol 2012, 49:223-227.
23. Mimura N., Hideshima T., Shimomura T., et al. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res 2014, 74:4458-4469.
24. Macario A.J., Conway de Macario E. Sick chaperones, cellular stress, and disease. N Engl J Med 2005, 353:1489-1501.
25. Garcia-Carbonero R., Carnero A., Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 2013, 14:e358-369.
26. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
27. Davenport E.L., Moore H.E., Dunlop A.S., et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 110:2641-2649.
28. Lawson B., Brewer J.W., Hendershot L.M. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway. J Cell Physiol 1998, 174:170-178.
29. Marcu M.G., Doyle M., Bertolotti A., Ron D., Hendershot L., Neckers L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 2002, 22:8506-8513.
30. Suzuki R., Hideshima T., Mimura N., et al. Anti-tumor activities of selective HSP90alpha/beta inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia 2015, 29:510-514.
31. Braunstein M.J., Scott S.S., Scott C.M., et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol 2011, 2011:232037.
32. Zhang L., Fok J.J., Mirabella F., et al. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett 2013, 339:49-59.
33. Davenport E.L., Zeisig A., Aronson L.I., et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010, 24:1804-1807.
34. Heimberger T., Andrulis M., Riedel S., et al. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol 2013, 160:465-476.
35. Chatterjee M., Andrulis M., Stuhmer T., et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013, 98:1132-1141.
36. Koong A.C., Chauhan V., Romero-Ramirez L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther 2006, 5:756-759.
37. Iwakoshi N.N., Lee A.H., Glimcher L.H. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev 2003, 194:29-38.
38. Munshi N.C., Hideshima T., Carrasco D., et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004, 103:1799-1806.
39. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003, 100:9946-9951.
40. Carrasco D.R., Sukhdeo K., Protopopova M., et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11:349-360.
41. Ali M.M., Bagratuni T., Davenport E.L., et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J 2011, 30:894-905.
42. Mimura N., Fulciniti M., Gorgun G., et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012, 119:5772-5781.
43. Ri M., Tashiro E., Oikawa D., et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J 2012, 2:e79.
44. Cross B.C., Bond P.J., Sadowski P.G., et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A 2012, 109:E869-E878.
45. Papandreou I., Denko N.C., Olson M., et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011, 117:1311-1314.
46. Xu G., Liu K., Anderson J., et al. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood 2012, 119:4205-4214.
47. Bae J., Carrasco R., Lee A.H., et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia 2011, 25:1610-1619.
48. Bae J., Prabhala R., Voskertchian A., et al. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 2015, 29:218-229.
49. Bae J., Smith R., Daley J., et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res 2012, 18:4850-4860.
50. Bagratuni T., Wu P., Gonzalez de Castro D., et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010, 116:250-253.
51. Ling S.C., Lau E.K., Al-Shabeeb A., et al. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica 2012, 97:64-72.
52. Gambella M., Rocci A., Passera R., et al. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica 2014, 99:e14-e16.
53. Leung-Hagesteijn C., Erdmann N., Cheung G., et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013, 24:289-304.
54. Michallet A.S., Mondiere P., Taillardet M., Leverrier Y., Genestier L., Defrance T. Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS One 2011, 6:e25820.
55. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2:927-937.
56. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
57. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
58. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929.
59. Younes H., Leleu X., Hatjiharissi E., et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cacer Res 2007, 13:3771-3775.
60. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
61. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
62. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
63. Pene F., Claessens Y.E., Muller O., et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002, 21:6587-6597.
64. Janku F., McConkey D.J., Hong D.S., Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011, 8:528-539.
65. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000.
66. Mitsiades C.S., Mitsiades N., Poulaki V., et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683.
67. Keane N.A., Glavey S.V., Krawczyk J., O'Dwyer M. AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets 2014, 18:897-915.
68. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., Sausville E.A., Roy K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003, 2:1093-1103.
69. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003, 14:167-173.
70. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
71. Gills J.J., Dennis P.A. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009, 11:102-110.
72. Ramakrishnan V., Kimlinger T., Haug J., et al. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One 2012, 7:e50005.
73. Mounir Z., Krishnamoorthy J.L., Wang S., et al. Akt determines cell fate through inhibition of the PERK-eIF2alpha phosphorylation pathway. Sci Signal 2011, 4:ra62.
74. Spencer A., Yoon S.S., Harrison S.J., et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood 2014, 124:2190-2195.
75. Cao H., Zhu K., Qiu L., et al. Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem 2013, 288:30399-30410.
76. Ikeda H., Hideshima T., Fulciniti M., et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010, 116:1460-1468.
77. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
78. Maiso P., Liu Y., Morgan B., et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011, 118:6860-6870.
79. Stengel C., Cheung C.W., Quinn J., Yong K., Khwaja A. Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. Leukemia 2012, 26:1761-1770.
80. Cirstea D., Santo L., Hideshima T., et al. Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther 2014, 13:2489-2500.
81. Morgan G.J., Walker B.A., Davies F.E. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012, 12:335-348.
82. Chang-Yew Leow C., Gerondakis S., Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 2013, 3:e105.
83. Steinbrunn T., Stuhmer T., Sayehli C., Chatterjee M., Einsele H., Bargou R.C. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol 2012, 159:430-440.
84. Chinen Y., Kuroda J., Shimura Y., et al. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma. Cancer Res 2014, 74:7418-7429.
85. Gilmore T.D. Multiple myeloma: lusting for NF-kappaB. Cancer Cell 2007, 12:95-97.
86. Hideshima T., Ikeda H., Chauhan D., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
87. Fabre C., Mimura N., Bobb K., et al. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res 2012, 18:4669-4681.
88. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
89. Dimopoulos K., Gimsing P., Gronbaek K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J 2014, 4:e207.
90. Smith E.M., Boyd K., Davies F.E. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 2010, 148:702-713.
91. Kaiser M.F., Johnson D.C., Wu P., et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood 2013, 122:219-226.
92. Walker B.A., Wardell C.P., Chiecchio L., et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood 2011, 117:553-562.
93. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
94. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
95. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
96. Choudhary C., Kumar C., Gnad F., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
97. Hideshima T., Anderson K.C. Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol 2013, 97:324-332.
98. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004, 101:540-545.
99. Catley L., Weisberg E., Tai Y.T., et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003, 102:2615-2622.
100. Catley L., Weisberg E., Kiziltepe T., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449.
101. Maiso P., Carvajal-Vergara X., Ocio E.M., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66:5781-5789.
102. Feng R., Oton A., Mapara M.Y., Anderson G., Belani C., Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007, 139:385-397.
103. Khan S.B., Maududi T., Barton K., Ayers J., Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004, 125:156-161.
104. Dimopoulos M., Siegel D.S., Lonial S., et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study. Lancet Oncol 2013, 14:1129-1140.
105. Richardson PG, Hungria VTM, Yoon S-S, et al. Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. ASCO Meeting Abstracts. 2014;32:8510.
106. Hideshima T., Bradner J.E., Wong J., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005, 102:8567-8572.
107. Santo L., Hideshima T., Kung A.L., et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119:2579-2589.
108. Quayle S.N., Jones S.S. ACY-1215, a first-in-class selective inhibitor of HDAC6, demonstrates significant synergy with immunomodulatory drugs (IMiDs) in preclinical models of multiple myeloma (MM). Blood 2013, 122:1952.
109. Vogl D.T., Raje N., Hari P., et al. Phase 1B results of ricolinostat (ACY-1215) combination therapy with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (MM). Blood 2014, 124:4764.
110. Yee A.J., Voorhees P.M., Bensinger W., et al. Ricolinostat (ACY-1215), a selective HDAC6 Inhibitor, in combination with lenalidomide and dexamethasone: results of a phase 1b trial in relapsed and relapsed refractory multiple myeloma. Blood 2014, 124:4772.
111. Hideshima T., Mazitschek R., Santo L., et al. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 2014, 28:457-460.
112. Minami J., Suzuki R., Mazitschek R., et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014, 28:680-689.
113. Wagner E.J., Carpenter P.B. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 2012, 13:115-126.
114. Martinez-Garcia E., Popovic R., Min D.J., et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011, 117:211-220.
115. Min D.J., Ezponda T., Kim M.K., et al. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia 2013, 27:686-694.
116. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin Cancer Res 2011, 17:2613-2618.
117. Kalushkova A., Fryknas M., Lemaire M., et al. Polycomb target genes are silenced in multiple myeloma. PLoS One 2010, 5:e11483.
118. Croonquist P.A., Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005, 24:6269-6280.
119. van Haaften G., Dalgliesh G.L., Davies H., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009, 41:521-523.
120. Rizq O., Mimura N., Koide S., et al. EZH2 Inhibition and the combination with proteasome inhibition are novel potential strategies for the treatment of multiple myeloma. Blood 2014, 124:2094.
121. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
122. Dimopoulos K., Gimsing P., Gronbaek K. Aberrant microRNA expression in nmultiple myeloma. Eur J Haematol 2013, 91:95-105.
123. Amodio N., Leotta M., Bellizzi D., et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012, 3:1246-1258.
124. Di Martino M.T., Leone E., Amodio N., et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012, 18:6260-6270.
125. Ahmad N., Haider S., Jagannathan S., Anaissie E., Driscoll J.J. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia 2014, 28:732-738.
126. Filippakopoulos P., Knapp S. The bromodomain interaction module. FEBS Lett 2012, 586:2692-2704.
127. Filippakopoulos P., Qi J., Picaud S., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
128. Delmore J.E., Issa G.C., Lemieux M.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
129. Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007, 138:563-579.
130. Bensinger W. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 2014, 28:891-902.
131. Lu G., Middleton R.E., Sun H., et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343:305-309.
132. Anderson K.C. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005, 42:S3-8.
133. Quach H., Ritchie D., Stewart A.K., et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24:22-32.
134. Gorgun G., Calabrese E., Soydan E., et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010, 116:3227-3237.
135. Okazaki T., Chikuma S., Iwai Y., Fagarasan S., Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013, 14:1212-1218.
136. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
137. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
138. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
139. Hamid O., Robert C., Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
140. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
141. Liu J., Hamrouni A., Wolowiec D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
142. Tamura H., Ishibashi M., Yamashita T., et al. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013, 27:464-472.
143. Benson D.M., Bakan C.E., Mishra A., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116:2286-2294.
144. Rosenblatt J., Glotzbecker B., Mills H., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011, 34:409-418.
145. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-12297.
146. Kearl T.J., Jing W., Gershan J.A., Johnson B.D. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013, 190:5620-5628.
147. Hallett W.H., Jing W., Drobyski W.R., Johnson B.D. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 2011, 17:1133-1145.
148. Atanackovic D., Luetkens T., Kroger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014, 28:993-1000.
149. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
150. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012, 12:253-268.
151. Gorgun G.T., Whitehill G., Anderson J.L., et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121:2975-2987.
152. Ramachandran I.R., Martner A., Pisklakova A., et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 2013, 190:3815-3823.
153. Serafini P., Meckel K., Kelso M., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006, 203:2691-2702.
154. Noonan K.A., Ghosh N., Rudraraju L., Bui M., Borrello I. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. Cancer Immunol Res 2014, 2:725-731.